109 Results

Eisai acquires US rights from Purdue Pharma to lemborexant for the treatment of multiple sleep-wake disorders.

 Added 1 month ago

Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma L.P.’s rights in the worldwide...

Phase III trial of AVP 786 shows dose response in Alzheimer's agitation

 Added 3 months ago

Avanir Pharmaceuticals announced the results from the first study of the company's phase III clinical development program investigating the efficacy, safety and tolerability of AVP 786...

Phase III (Clarity AD/Study 301) of BAN 2401 is initiated for early Alzheimer's disease

 Added 3 months ago

Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN 2401, an anti-amyloid beta...

Eisai and Biogen discontinue phase III trials, ENGAGE and EMERGE

 Added 3 months ago

Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase III trials, ENGAGE and EMERGE, designed to...

Genentech/Roche cancels CREED-1 and d CREED 2 Phase III trials of crenezumab for Alzheimer's Disease

 Added 4 months ago

Genentech, a member of the Roche Group, announced the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553)...

Phase III clinical trial of GV 971 shows promise in Alzheimers disease.- Green Valley Pharma.

 Added 8 months ago

Green Valley Pharmaceutical Co announced promising findings from a Phase III clinical trial of GV 971, a multi targeting carbohydrate-based...

Global survey investigating perceptions of Alzheimer's disease-Novartis + Amgen + Banner.

 Added 9 months ago

Novartis, Amgen and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest global...

Successful Phase III A16 study of flortaucipir F 18 , a PET agent to predict Alzheimers disease diagnosis. - Eli Lilly.

 Added 9 months ago

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced that a Phase III study...

Global phase III trials of lanabecestat in Alzheimers disease discontinued.- AstraZeneca + Eli Lilly.

 Added 1 year ago

AstraZeneca and Eli Lilly are discontinuing the global Phase III clinical trials of lanabecestat, for the treatment of Alzheimer’s disease....

Load more